Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 9, 2026, 11:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,242 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug Interaction Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

NCT07015398
View directory record Official record
Conditions
Healthy Participants
Interventions
NAL ER, Pirfenidone, Nintedanib
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Non-Specific Effects of Manual Therapy

NCT03017534
View directory record Official record
Conditions
Musculoskeletal Manipulations, Placebo Effect
Interventions
Spinal Manual Therapy
Procedure
Lead sponsor
Shenandoah University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Winchester, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Interactive Motivational Media for Perinatal Drug Abuse - 3

NCT00230048
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Brief computer-delivered intervention
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2006
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants

NCT04545944
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan, Midazolam
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction & Methadone & Buprenorphine

NCT02045693
View directory record Official record
Conditions
Hepatitis C
Interventions
Methadone, DCV 3DAA FDC, BMS-791325, Buprenorphine, Naloxone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
3
States / cities
Anaheim, California • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects

NCT00666796
View directory record Official record
Conditions
Insomnia
Interventions
Placebo ethanol, Ethanol, Placebo, Gabapentin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study in Healthy Adult Volunteers

NCT02275962
View directory record Official record
Conditions
Healthy
Interventions
K-877, Rifampin
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

NCT06593457
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IP, Matching Placebo
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion

NCT02085967
View directory record Official record
Conditions
Healthy Subjects
Interventions
rifampin 600 mg, itraconazole 200 mg, midazolam 2 mg with bupropion 75 mg, E2006
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine

NCT01540500
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tasimelteon, Fluvoxamine
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 16, 2014 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma

NCT01691807
View directory record Official record
Conditions
Cancer
Interventions
ofatumumab, bendamustine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Birmingham, Alabama • Southaven, Mississippi • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.

NCT03927677
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Xanthine Oxidase Inhibitor
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects

NCT01189500
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Tamoxifen, Tamoxifen and Desvenlafaxine Succinate Sustained Release
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex

NCT00000986
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water

NCT00768183
View directory record Official record
Conditions
Healthy
Interventions
KADIAN Capsule + alcohol (under fasting conditions), KADIAN Capsule + water (under fasting conditions), morphine sulfate IR oral solution + water, KADIAN Capsule + alcohol (under fed conditions)
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
21 Years to 40 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Jun 9, 2026, 11:48 PM EDT
Terminated Phase 1 Interventional Results available

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

NCT04865419
View directory record Official record
Conditions
Haematological Malignancies
Interventions
AZD0466, Voriconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Duarte, California • Jacksonville, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Drug Interaction Between Multiple Doses of Ketoconazole and a Single Dose of SKI-606

NCT00434486
View directory record Official record
Conditions
Healthy
Interventions
SKI-606
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2007 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Not applicable Interventional

A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS

NCT00002034
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Zidovudine, Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Birmingham, Alabama • Oakland, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 4 Interventional

Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.

NCT00414102
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 64 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Jun 9, 2026, 11:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole

NCT01094275
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel 75mg, Omeprazole 20mg
Drug
Lead sponsor
Neil Kleiman, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jun 9, 2026, 11:48 PM EDT
Recruiting No phase listed Observational

The Role of Brain-Bone Marrow-Gut Interaction Following Major Trauma

NCT06606119
View directory record Official record
Conditions
Trauma Injury, Trauma, Critical Illness, Microbiome, Chronic Anemia, Acute Blood Loss Anemia
Interventions
Data and tissue collection
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

NCT05906836
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants

NCT04515628
View directory record Official record
Conditions
Healthy Participants
Interventions
Rosuvastatin, Branebrutinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Jun 9, 2026, 11:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Between Rifampin and Fluvastatin

NCT04029584
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
rifampin IV, Rifadin 300Mg Capsule, Fluvastatin 20 MG
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jun 9, 2026, 11:48 PM EDT